398 related articles for article (PubMed ID: 27658863)
1. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
[TBL] [Abstract][Full Text] [Related]
2. Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
Tapia G; Højen JF; Ökvist M; Olesen R; Leth S; Nissen SK; VanBelzen DJ; O'Doherty U; Mørk A; Krogsgaard K; Søgaard OS; Østergaard L; Tolstrup M; Pantaleo G; Sommerfelt MA
J Infect; 2017 Dec; 75(6):555-571. PubMed ID: 28917661
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
4. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
[TBL] [Abstract][Full Text] [Related]
5. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS
Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074
[TBL] [Abstract][Full Text] [Related]
6. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
Søgaard OS; Graversen ME; Leth S; Olesen R; Brinkmann CR; Nissen SK; Kjaer AS; Schleimann MH; Denton PW; Hey-Cunningham WJ; Koelsch KK; Pantaleo G; Krogsgaard K; Sommerfelt M; Fromentin R; Chomont N; Rasmussen TA; Østergaard L; Tolstrup M
PLoS Pathog; 2015 Sep; 11(9):e1005142. PubMed ID: 26379282
[TBL] [Abstract][Full Text] [Related]
7. Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.
Winckelmann A; Morcilla V; Shao W; Schleimann MH; Hojen JF; Schlub TE; Denton PW; Østergaard L; Søgaard OS; Tolstrup M; Palmer S
AIDS; 2018 Aug; 32(13):1793-1802. PubMed ID: 29762162
[TBL] [Abstract][Full Text] [Related]
8. Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
Rockstroh JK; Asmuth D; Pantaleo G; Clotet B; Podzamczer D; van Lunzen J; Arastéh K; Mitsuyasu R; Peters B; Silvia N; Jolliffe D; Ökvist M; Krogsgaard K; Sommerfelt MA
PLoS One; 2019; 14(1):e0210965. PubMed ID: 30699178
[TBL] [Abstract][Full Text] [Related]
9. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
Moron-Lopez S; Kim P; Søgaard OS; Tolstrup M; Wong JK; Yukl SA
AIDS; 2019 Mar; 33(3):425-431. PubMed ID: 30531314
[TBL] [Abstract][Full Text] [Related]
12. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
13. Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.
Gandhi RT; Bosch RJ; Aga E; Bedison MA; Bastow B; Schmitz JL; Siliciano JD; Siliciano RF; Eron JJ; Mellors JW;
Antivir Ther; 2013; 18(4):607-13. PubMed ID: 23411421
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.
Winckelmann A; Barton K; Hiener B; Schlub TE; Shao W; Rasmussen TA; Østergaard L; Søgaard OS; Tolstrup M; Palmer S
AIDS; 2017 Mar; 31(6):771-779. PubMed ID: 28272134
[TBL] [Abstract][Full Text] [Related]
15. Postvaccination C-Reactive Protein and C5/gp41
Huang Y; Zhang L; Jolliffe D; Sanchez B; Stjernholm G; Jelmert Ø; Ökvist M; Sommerfelt MA
AIDS Res Hum Retroviruses; 2018 Mar; 34(3):307-313. PubMed ID: 29297230
[TBL] [Abstract][Full Text] [Related]
16. Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.
Huang Y; Pantaleo G; Tapia G; Sanchez B; Zhang L; Trondsen M; Hovden AO; Pollard R; Rockstroh J; Ökvist M; Sommerfelt MA
EBioMedicine; 2017 Oct; 24():195-204. PubMed ID: 28970080
[TBL] [Abstract][Full Text] [Related]
17. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.
Persaud D; Luzuriaga K; Ziemniak C; Muresan P; Greenough T; Fenton T; Blackford A; Ferguson K; Neu N; Cunningham CK
AIDS; 2011 Nov; 25(18):2227-34. PubMed ID: 21918423
[TBL] [Abstract][Full Text] [Related]
18. HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).
Mothe B; Rosás-Umbert M; Coll P; Manzardo C; Puertas MC; Morón-López S; Llano A; Miranda C; Cedeño S; López M; Alarcón-Soto Y; Melis GG; Langohr K; Barriocanal AM; Toro J; Ruiz I; Rovira C; Carrillo A; Meulbroek M; Crook A; Wee EG; Miró JM; Clotet B; Valle M; Martinez-Picado J; Hanke T; Brander C; Moltó J;
Front Immunol; 2020; 11():823. PubMed ID: 32435247
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART.
Fagard C; Le Braz M; Günthard H; Hirsch HH; Egger M; Vernazza P; Bernasconi E; Telenti A; Ebnöther C; Oxenius A; Perneger T; Perrin L; Hirschel B;
AIDS; 2003 Jul; 17(10):1487-92. PubMed ID: 12824786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
